JP2019524768A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019524768A5 JP2019524768A5 JP2019505179A JP2019505179A JP2019524768A5 JP 2019524768 A5 JP2019524768 A5 JP 2019524768A5 JP 2019505179 A JP2019505179 A JP 2019505179A JP 2019505179 A JP2019505179 A JP 2019505179A JP 2019524768 A5 JP2019524768 A5 JP 2019524768A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- l1cam
- cancer
- administered
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022092913A JP2022118058A (ja) | 2016-08-02 | 2022-06-08 | 転移性がんの処置および転移性疾患のためのモデルシステム |
| JP2025030120A JP2025078664A (ja) | 2016-08-02 | 2025-02-27 | 転移性がんの処置および転移性疾患のためのモデルシステム |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662370108P | 2016-08-02 | 2016-08-02 | |
| US62/370,108 | 2016-08-02 | ||
| PCT/US2017/045145 WO2018026947A1 (en) | 2016-08-02 | 2017-08-02 | Treating metastatic cancer and model systems for metastatic disease |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022092913A Division JP2022118058A (ja) | 2016-08-02 | 2022-06-08 | 転移性がんの処置および転移性疾患のためのモデルシステム |
| JP2025030120A Division JP2025078664A (ja) | 2016-08-02 | 2025-02-27 | 転移性がんの処置および転移性疾患のためのモデルシステム |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019524768A JP2019524768A (ja) | 2019-09-05 |
| JP2019524768A5 true JP2019524768A5 (https=) | 2020-09-10 |
| JP7751372B2 JP7751372B2 (ja) | 2025-10-08 |
Family
ID=61073928
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019505179A Active JP7751372B2 (ja) | 2016-08-02 | 2017-08-02 | 転移性がんの処置および転移性疾患のためのモデルシステム |
| JP2022092913A Pending JP2022118058A (ja) | 2016-08-02 | 2022-06-08 | 転移性がんの処置および転移性疾患のためのモデルシステム |
| JP2025030120A Pending JP2025078664A (ja) | 2016-08-02 | 2025-02-27 | 転移性がんの処置および転移性疾患のためのモデルシステム |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022092913A Pending JP2022118058A (ja) | 2016-08-02 | 2022-06-08 | 転移性がんの処置および転移性疾患のためのモデルシステム |
| JP2025030120A Pending JP2025078664A (ja) | 2016-08-02 | 2025-02-27 | 転移性がんの処置および転移性疾患のためのモデルシステム |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11464874B2 (https=) |
| EP (2) | EP3493846B1 (https=) |
| JP (3) | JP7751372B2 (https=) |
| KR (2) | KR20190036553A (https=) |
| AU (2) | AU2017306426B2 (https=) |
| CA (1) | CA3029653A1 (https=) |
| ES (1) | ES3037528T3 (https=) |
| IL (1) | IL264024A (https=) |
| WO (1) | WO2018026947A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9719068B2 (en) | 2010-05-06 | 2017-08-01 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
| SG10201801654RA (en) | 2014-05-28 | 2018-04-27 | Childrens Hospital Med Ct | Methods and systems for converting precursor cells into gastric tissues through directed differentiation |
| AU2015331848B2 (en) | 2014-10-17 | 2022-03-03 | Children's Hospital Medical Center, D/B/A Cincinnati Children's Hospital Medical Center | In vivo model of human small intestine using pluripotent stem cells and methods of making and using same |
| CN109415685B (zh) | 2016-05-05 | 2023-07-04 | 儿童医院医疗中心 | 用于体外制造胃底组织的方法和与其相关的组合物 |
| EP4553082A3 (en) | 2016-11-04 | 2025-08-20 | Children's Hospital Medical Center | Liver organoid compositions and methods of making and using same |
| EP3548507A4 (en) | 2016-12-05 | 2020-07-15 | Children's Hospital Medical Center | COLON ORGANOIDS AND PROCESSES FOR THE PREPARATION AND USE THEREOF |
| JP7248586B2 (ja) | 2017-04-14 | 2023-03-29 | チルドレンズ ホスピタル メディカル センター | 複数ドナー幹細胞組成物およびそれを作製する方法 |
| EP3694603B1 (en) | 2017-10-10 | 2026-04-08 | Children's Hospital Medical Center | Esophageal tissue and/or organoid compositions and methods of making same |
| EP3727394A4 (en) | 2017-12-21 | 2021-09-08 | Children's Hospital Medical Center | DIGITALIZED HUMAN ORGANOIDS AND METHOD OF USING THEREOF |
| WO2020003210A1 (en) | 2018-06-29 | 2020-01-02 | Kangwon National University University-Industry Cooperation Foundation | Anti-l1cam antibodies and uses thereof |
| EP4678727A3 (en) | 2018-07-26 | 2026-03-11 | Children's Hospital Medical Center | Hepato-biliary-pancreatic tissues and methods of making same |
| CA3112026A1 (en) | 2018-09-12 | 2020-03-19 | Children's Hospital Medical Center | Organoid compositions for the production of hematopoietic stem cells and derivatives thereof |
| US12600943B2 (en) | 2019-02-01 | 2026-04-14 | The University Of Hong Kong | Innervated organoid compositions and methods of making same |
| AU2020283048A1 (en) | 2019-05-31 | 2021-12-23 | Children's Hospital Medical Center | Shaped organoid compositions and methods of making same |
| US12497597B2 (en) | 2019-05-31 | 2025-12-16 | Children's Hospital Medical Center | Methods of generating and expanding hematopoietic stem cells |
| WO2023102120A1 (en) * | 2021-12-01 | 2023-06-08 | Memorial Sloan-Kettering Cancer Center | Organoid co-cultures and methods of use thereof |
| CN115078738A (zh) * | 2022-06-30 | 2022-09-20 | 复旦大学 | 一种l1cam蛋白n979位点特异性核心岩藻糖基化的抑制剂的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007114550A1 (en) | 2006-04-03 | 2007-10-11 | Korea Research Institute Of Bioscience And Biotechnology | A novel monoclonal antibody specific to the l1cam, a hybridoma producing the same and a method producing the same |
| CA2661669C (en) * | 2006-08-23 | 2017-02-14 | Korea Research Institute Of Bioscience And Biotechnology | A pharmaceutical composition for treating cholangiocarcinoma, a method for inhibiting growth or invasion of cholangiocarcinoma and a method for treating cholangniocarcinoma |
| WO2008046459A1 (en) * | 2006-10-16 | 2008-04-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Treatment of chemotherapy- or radiotherapy-resistant tumors using an l1 interfering molecule |
| AU2007221863A1 (en) * | 2006-10-16 | 2008-05-01 | Deutsches Krebsforschungszentrum Stiftung Des Offenftlichen Rechts | Treatment of chemotherapy -or radiothereapy-resistant tumors |
| LT2631248T (lt) | 2007-06-15 | 2018-04-25 | Medigene Ag | Navikų gydymas, naudojant specifinį anti-l1 antikūną |
| AU2008201871A1 (en) * | 2008-04-16 | 2009-11-26 | Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts | Inhibition of angiogenesis and tumor metastasis |
| KR20100060351A (ko) * | 2008-11-27 | 2010-06-07 | 한국생명공학연구원 | Ｌ１ｃａｍ의 활성 또는 발현을 억제하는 물질 및 항암제를포함하는 항암용 조성물 |
| WO2011146382A1 (en) * | 2010-05-17 | 2011-11-24 | Bristol-Myers Squibb Company | Improved immunotherapeutic dosing regimens and combinations thereof |
| KR101271964B1 (ko) | 2010-07-08 | 2013-06-07 | 강원대학교산학협력단 | 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법 |
| EP2931899A1 (en) | 2012-12-12 | 2015-10-21 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
| EP4286517A3 (en) | 2013-04-04 | 2024-03-13 | President and Fellows of Harvard College | Therapeutic uses of genome editing with crispr/cas systems |
| EP3047039B1 (en) * | 2013-09-18 | 2019-07-31 | Memorial Sloan-Kettering Cancer Center | Inhibiting cancer metastasis |
| WO2015048577A2 (en) * | 2013-09-27 | 2015-04-02 | Editas Medicine, Inc. | Crispr-related methods and compositions |
| CN104829730A (zh) * | 2015-04-14 | 2015-08-12 | 苏静 | 一种能联合免疫细胞增强肿瘤杀伤能力的双特异性抗体及其制备方法和应用 |
-
2017
- 2017-08-02 KR KR1020197006250A patent/KR20190036553A/ko not_active Ceased
- 2017-08-02 CA CA3029653A patent/CA3029653A1/en active Pending
- 2017-08-02 ES ES17837622T patent/ES3037528T3/es active Active
- 2017-08-02 EP EP17837622.4A patent/EP3493846B1/en active Active
- 2017-08-02 EP EP25174512.1A patent/EP4623998A3/en active Pending
- 2017-08-02 WO PCT/US2017/045145 patent/WO2018026947A1/en not_active Ceased
- 2017-08-02 KR KR1020237042034A patent/KR20230170142A/ko active Pending
- 2017-08-02 JP JP2019505179A patent/JP7751372B2/ja active Active
- 2017-08-02 AU AU2017306426A patent/AU2017306426B2/en active Active
-
2018
- 2018-12-30 IL IL264024A patent/IL264024A/en unknown
-
2019
- 2019-01-31 US US16/263,677 patent/US11464874B2/en active Active
-
2022
- 2022-06-08 JP JP2022092913A patent/JP2022118058A/ja active Pending
- 2022-10-10 US US18/045,357 patent/US12059480B2/en active Active
-
2024
- 2024-08-12 US US18/800,616 patent/US20250213731A1/en active Pending
- 2024-12-31 AU AU2024287267A patent/AU2024287267A1/en active Pending
-
2025
- 2025-02-27 JP JP2025030120A patent/JP2025078664A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019524768A5 (https=) | ||
| Beatty et al. | The biological underpinnings of therapeutic resistance in pancreatic cancer | |
| Rybinski et al. | Addressing intra-tumoral heterogeneity and therapy resistance | |
| Gao et al. | LncRNA PCAT1 activates SOX2 and suppresses radioimmune responses via regulating cGAS/STING signalling in non‐small cell lung cancer | |
| Yu et al. | NEAT 1: A novel cancer‐related long non‐coding RNA | |
| Iacono et al. | Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study | |
| McIntyre et al. | PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy | |
| Bandapalli et al. | NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia | |
| Wong et al. | The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2 | |
| Leblanc et al. | Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma | |
| Kang et al. | Stathmin1 plays oncogenic role and is a target of microRNA-223 in gastric cancer | |
| Fan et al. | Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration | |
| Wang et al. | High-throughput chemical screening identifies focal adhesion kinase and Aurora kinase B inhibition as a synergistic treatment combination in Ewing sarcoma | |
| Sakaizawa et al. | Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level | |
| Han et al. | MicroRNA-106a regulates autophagy-related cell death and EMT by targeting TP53INP1 in lung cancer with bone metastasis | |
| Sung et al. | FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy | |
| Chhabra et al. | MicroRNAs in cancer stem cells: current status and future directions | |
| Eoh et al. | MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis | |
| Mariani et al. | HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer | |
| Lennerz et al. | Suppressor of cytokine signaling 1 gene mutation status as a prognostic biomarker in classical Hodgkin lymphoma | |
| RU2017134347A (ru) | Способы лечения рака, имеющего гемизиготную потерю тр53 | |
| Dzhugashvili et al. | Role of genetic polymorphisms in NFKB-mediated inflammatory pathways in response to primary chemoradiation therapy for rectal cancer | |
| Roth et al. | Employing an orthotopic model to study the role of epithelial-mesenchymal transition in bladder cancer metastasis | |
| Sivanathan et al. | In vivo passage of human prostate cancer cells in mice results in stable gene expression changes affecting numerous cancer‐associated biological processes | |
| Uzunoglu et al. | CXC motif receptor 2, endostatin and proteinase-activated receptor 1 polymorphisms as prognostic factors in NSCLC |